Drug

Tazemetostat

In clinical development

Emerging researchLate-stage development

Also known as Tazverik, Tazémétostat, Tazemetostatum.

RxNorm2274378 ChEMBLCHEMBL3414621 ATCL01XX72UNIIQ40W93WPE1

Research papers

Active clinical trials

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma

Clinical trial2026-07-01Results expected Q1 2027 · ClinicalTrials.gov

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol

Clinical trial2026-06-17Results posted · ClinicalTrials.gov

A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma

Clinical trial2026-06-15Results posted · ClinicalTrials.gov

A Pilot Study of Tazemetostat and Pembrolizumab (MK-3475) in Advanced Urothelial Carcinoma

Clinical trial2026-06-11Results expected Q2 2027 · ClinicalTrials.gov

Phase 2 Study Using Tazemetostat in Patients With Recurrent/Refractory and/or Metastatic Malignant Peripheral Nerve Sheath Tumors (MPNST)

Clinical trial2026-06-04Results posted · ClinicalTrials.gov

Phase 1/Expansion Study of Tazemetostat Plus Belinostat for the Treatment of Relapsed or Refractory Lymphoma

Clinical trial2026-05-13Results expected Q3 2026 · ClinicalTrials.gov

Phase II, Single Arm, Open Label, Study of the Combination of Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-Cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

Clinical trial2026-05-07Results expected Q2 2027 · ClinicalTrials.gov

A Single Arm Phase I/II Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma Big Ten Cancer Research Consortium BTCRC-LYM20-463

Clinical trial2026-05-01Primary completion · ClinicalTrials.gov

A Multicenter, Open-label, Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of SHR-4394 in Combination With Anti-tumor Therapy in Participants With Prostate Cancer

Clinical trial2026-04-21Results expected Q4 2027 · ClinicalTrials.gov

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Tazemetostat in Patients With Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex

Clinical trial2026-04-13Results posted · ClinicalTrials.gov

TAZNI: A Phase I/II Combination Trial of Tazemetostat With Nivolumab and Ipilimumab for Children With INI1-Negative or SMARCA4-Deficient Tumors

Clinical trial2026-04-13Results expected Q1 2027 · ClinicalTrials.gov

EZH2: a novel target for cancer treatment.

Research2020-07-28Journal of hematology & oncology

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Tazemetostat

Aliases & brands

TazverikTazémétostatTazemetostatum

RxNorm CUI

2274378

ChEMBL ID

CHEMBL3414621

ATC codes

L01XX72

UNII

Q40W93WPE1

Clinical trials

46 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme

CLINICALTRIALS.GOV · LIVE REGISTRY

registered trials across all phases

LATEST COMPLETION 2025

Active studies

Recruiting

Late-stage (III+)

Completed

Discontinued

PHASE DISTRIBUTIONn = 46

Phase 114Phase 1 / 213Phase 218Phase 31

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Active, not recruitingPH IIIEpizyme, Inc.n=5992029

Recent completions

Trials that read out recently, adding to the completed evidence base.

Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study

CompletedPH I/IIEpizyme, Inc.n=582025

Combining Epigenetic And Immune Therapy to Beat Cancer. CAIRE Study

CompletedPH IIInstitut Bergonién=1642025

A Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Tazemetostat in Combination With HMPL-689 in Patients With Relapsed/Refractory Lymphoma

CompletedPH IIHutchmedn=612024

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Tazemetostat in Patients With Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex

CompletedPH IINational Cancer Institute (NCI)n=202024

A Multicenter, Open-label, Phase II Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Tazemetostat for the Treatment of Patients With Relapsed/Refractory Follicular Lymphoma

CompletedPH IIHutchmedn=422024

A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma

CompletedPH IIEpizyme, Inc.n=2672024

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Most influential

EZH2: a novel target for cancer treatment.

Journal of hematology & oncology · 2020 · 712 cites

Related drugs

1 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Adenosine

Studied across 3 of the same disease areas as Tazemetostat in the shared literature.

3 shared diseases1 shared paper

References & data sources

RxNorm (U.S. National Library of Medicine) — drug identity
ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
Europe PMC — research literature
ClinicalTrials.gov — clinical trials